Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2015

Conditions
Metastatic Pancreatic CancerPancreatic Cancer
Interventions
DRUG

Folfirinox

"* Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~* Leucovorin 400 mg/m2 IV over two hours~* Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~* 5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."

Trial Locations (1)

06510

Smilow Cancer Center, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT01523457 - Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter